2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Nadiifinta ≥98.0% Olaparib Warshada Dhexe
Nadiif Sarreysa, Wax Soo Saarka Ganacsiga
Olaparib iyo Dhexdhexaadiyeyaasha la xidhiidha:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl) Piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Magaca Kiimikada | 2-Fluoro-5-Formylbenzonitrile |
| La mid ah | 3-Cyano-4-Fluorobenzaldehyde |
| Lambarka CAS | 218301-22-5 |
| Lambarka CAT | RF-PI451 |
| Heerka Saamiyada | Kaydka dhexdiisa, Qiyaasta Waxsoosaarka Ilaa Tan |
| Qaanuunka molecular | C8H4FNO |
| Miisaanka Molecular | 149.12 |
| Meesha dhalaalaysa | 80.0 ilaa 84.0 ℃ ( shid) |
| Solubility | Ku milma Methanol |
| Summada | Kiimikada Ruifu |
| Shayga | Tilmaamaha |
| Muuqashada | Jaalle iyo Budo-cad-cad |
| daahirnimo | ≥98.0% |
| Qoyaanka (KF) | ≤0.50% |
| Wadarta wasakhda | ≤2.0% |
| Heerka Imtixaanka | Heerka Ganacsiga |
| Isticmaalka | Dhexdhexaadiyaha Olaparib (CAS: 763113-22-0) PARP-Inhibitor |
Xidhmada: Dhalo, Bac aluminium biil ah, Durbaan kartoonada, 25kg/Drum, ama sida waafaqsan shuruudaha macmiilka.
Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka.
2-Fluoro-5-Formylbenzonitrile (CAS: 218301-22-5) waxaa loo isticmaalaa diyaarinta xeryahooda heterocyclic sida inhibitors PARP ee isticmaalka caafimaadka.2-Fluoro-5-Formylbenzonitrile waxa loo istcimaalaa dhex dhexaadinta Olaparib (CAS: 763113-22-0).Olaparib waa xakameyn yar oo molecule-ka ah PARP1/PARP2 (IC50: 5/1 nM) laakiin waa ka waxtar yar yahay PARP tankyrase-1 (IC50: 1.5 µM).Olaparib (AZD-2281, magaca ganacsiga Lynparza) waa daawaynta bartilmaameedka ah ee FDA-ansixisay ee kansarka, oo ay samaysay KuDOS Pharmaceuticals kadibna ay samaysay AstraZeneca.Waa PARP inhibitor, oo joojisa poly ADP ribose polymerase (PARP), enzyme ku lug leh hagaajinta DNA-da. Waxay ka hortagtaa kansarka dadka qaba isbeddellada BRCA1 ama BRCA2, oo ay ku jiraan qaar ka mid ah kansarka ugxan-sidaha, naaska, iyo qanjirka 'prostate'.Bishii Disembar 2014, olaparib waxaa loo oggolaaday in loo isticmaalo sidii wakiil keliya EMA iyo FDA.Oggolaanshaha FDA waxa uu u yaalaa germline BRCA mutated (gBRCAm) kansarka ugxansidaha horumarsan kaas oo helay saddex ama in ka badan oo hore oo kiimiko ah.
